VivoSim Labs, Inc. reported its financial results for the three months ended June 30, 2025, revealing a total revenue of $37,000, a slight increase from $25,000 in the same period last year. The company’s revenue primarily stemmed from royalty income, which rose by 48% year-over-year, while product revenue was non-existent, reflecting the cessation of operations in its former Mosaic division. The net loss for the quarter was $2.843 million, a decrease from a loss of $3.344 million in the prior year, resulting in a net loss per share of $1.14 compared to $2.74.
In terms of operational efficiency, VivoSim Labs reduced its total costs and expenses to $2.952 million from $3.425 million a year earlier, marking a 14% decrease. Research and development expenses fell by 29% to $1.001 million, attributed to a reduction in personnel from an average of 15 employees to 10. Selling, general, and administrative expenses also saw a minor decline of 3%, totaling $1.951 million. The company’s cash and cash equivalents decreased to approximately $9.1 million from $11.3 million at the end of the previous quarter, while total current assets were reported at $9.679 million.
Strategically, VivoSim Labs underwent significant changes, including the sale of its FXR program for $10 million in March 2025, which has provided the company with additional liquidity. The company has also rebranded itself from Organovo Holdings, Inc. to VivoSim Labs, Inc. to better align with its focus on 3D human tissue models for drug testing. The company is advancing its Preclinical IBD Program, aiming to submit an Investigational New Drug application to the FDA by December 2026.
As of June 30, 2025, VivoSim Labs had total liabilities of $2.440 million, down from $4.158 million in the previous quarter. The company’s working capital stood at $7.6 million, indicating a solid liquidity position despite ongoing operational losses. VivoSim Labs continues to seek additional funding to support its operations, with plans to raise capital through equity or debt financing. The company has expressed concerns regarding its ability to continue as a going concern, emphasizing the need for substantial additional funding to sustain its business model and operational activities in the coming year.
About VivoSim Labs, INC.
VivoSim Labs, Inc. specializes in providing testing services using 3D human tissue models of liver and intestine for drug safety and toxicology assessment. The company develops and offers bespoke toxicology insights, supporting pharmaceutical and biotech clients throughout drug development. Leveraging proprietary bioprinting and tissue engineering technologies, VivoSim aims to reduce drug development risks and costs, with a focus on non-animal testing methodologies and advanced disease models.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.